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Cyclin D1 is a critical regulator of androgen-dependent transcription and cell cycle progression in prostate cancer cells. Despite the
influence of D-type cyclins on prostate cancer proliferation, few studies have examined the expression of cyclin D1 in localised
tumours or challenged its relevance to disease progression. Cyclin D1 status was characterised using immunohistochemistry in 38
non-neoplastic prostate samples, 138 primary human prostate carcinomas, and three lymph node metastatic specimens. Relevance of
cyclin D1 to preoperative prostate-specific antigen (PSA) levels, Ki-67 index, and p21
Cip1 status was also examined. Cyclin D1-
positive phenotype was increased in primary carcinoma compared to non-neoplastic tissue, and was evident in all lymph node
metastases cases. Interestingly, at least three distinct localisation patterns were observed in the cyclin D1-positive cohort, wherein
cytoplasmic localisation was identified in a large fraction, and this pattern was predominant in lower grade tumours. Relevance of
altered cyclin D1 status was observed, wherein cyclin D1-positive tumours were associated with low preoperative PSA levels,
consistent with in vitro reports that cyclin D1 may alter the expression of this tumour marker. Moreover, tumours with predominantly
cytoplasmic cyclin D1 showed the lowest Ki-67 index, whereas nuclear cyclin D1 was associated with higher grade, elevated Ki-67,
and increased nuclear p21
Cip1. These data demonstrate that differential cyclin D1 status may influence clinicopathological parameters,
and reveal new insight as to the regulation and potential consequence of cyclin D1 expression in prostate cancer.
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Prostatic adenocarcinoma is the most commonly diagnosed
malignancy in the US, and is a leading cause of cancer death in
men (Jemal et al, 2006). This tumor type is dependent on androgen
for growth and survival, and treatment for metastatic disease
capitalises on this dependence. Androgen elicits its biologic effects
through activation of the androgen receptor (AR), a ligand-
dependent transcription factor that belongs to the nuclear receptor
superfamily (Trapman, 2001; Asatiani and Gelmann, 2005; Gao
et al, 2005). Upon ligand binding, activated AR stimulates a gene
expression program that induces cellular proliferation. As such,
first line therapy for disseminated prostate cancer entails ablation
of AR activity, either through deprivation of ligand or through the
use of direct AR antagonists (Sonpavde et al, 2006). These
therapies are highly effective, and result in tumour cell death or
cell cycle arrest (Agus et al, 1999). Moreover, therapeutic efficacy is
clinically monitored by reductions in serum PSA (prostate specific
antigen), as expression of PSA is dependent on AR activity in
prostatic cells and correlates with tumour burden (Catalona and
Loeb, 2005). Despite the initial success of therapy, recurrent
tumours ultimately form wherein AR activity has been restored,
and this event is typically preceded by a detectable rise in serum
PSA (Feldman and Feldman, 2001). Restoration of AR activity is
known to occur through several discrete pathways, and in model
systems of prostate cancer reactivation of AR is causative for
therapeutic relapse and tumour recurrence (Chen et al, 2004).
Moreover, the majority of studies have shown that recurrent,
androgen-independent prostate cancer cells still require AR
activity for proliferation and survival (Taplin and Balk, 2004;
Haag et al, 2005).
Given the importance of androgen action and AR function in
prostate cancer growth and progression, much emphasis has been
devoted to delineating the mechanisms by which AR promotes
tumour cell proliferation and the factors that govern these events.
Toward this end, we and others have shown that as part of its
proproliferative program, androgen induces accumulation of D-
type cyclins (Knudsen et al, 1998; Xu et al, 2006). This class of
cyclins interact with and activate cyclin-dependent kinases (CDK)
4/6 to promote G1 progression during the cell cycle (Mittnacht,
1998; Sherr and Roberts, 2004). Recent studies have shown that AR
stimulates cell cycle progression at least in part through induction
of mTOR (mammalian Target of Rapamycin) activity, which
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Additional factors are also suspected to control this event, such
as p21
Cip1, which is an essential accessory factor for the assembly,
stabilisation, and translocation of active cyclin D1/CDK4 com-
plexes to the nucleus (Cheng et al, 1999; Parry et al, 1999).
Furthermore, p21
Cip1 protein levels are induced by androgen
stimulation (Knudsen et al, 1998) and p21
Cip1 has been shown to
be a direct AR target gene (Lu et al, 1999). Displacement of p21
Cip1
from active cyclin D1/CDK4 complexes allows p21
Cip1 to bind and
inhibit CDK2 activity, thereby inhibiting progression through G1
and into S phase (Sherr and Roberts, 2004). Thus, the ability of
cyclin D1 to interact with p21
Cip1 is thought to be a critical
function in promoting cellular proliferation and is often associated
with mitogenic stimulation (Alt et al, 2002).
In prostate cancer cells, it has been shown that cyclin D1
induction is insufficient to drive androgen-independent prolifera-
tion (Knudsen et al, 1998; Fribourg et al, 2000), and forced
elevation of cyclin D1 in the presence of androgen suppresses
rather than promotes cellular proliferation (Petre-Draviam et al,
2003). These effects are at least partially attributed to the ability
of cyclin D1 to bind and inhibit AR activity (Knudsen et al, 1999;
Reutens et al, 2001), as achieved through at least two discrete
mechanisms. First, cyclin D1 binds an N-terminal region of AR
that is required for docking to its C terminus upon ligand
binding and suppresses the efficacy of this N–C interaction
(Burd et al, 2005). Second, cyclin D1 can associate with histone
deacetylases to repress transcription, and this function of cyclin
D1 is essential for its AR corepressor activity (Lin et al, 2002;
Petre-Draviam et al, 2005). Cyclin D1 can also bind to and
modulate other transcription factors by similar mechanisms,
with the largest class of proteins belonging to the nuclear receptor
superfamily (Coqueret, 2002; Ewen and Lamb, 2004; Fu et al,
2004). These collective observations have culminated in a model
whereby androgen-mediated induction of cyclin D1 serves to
activate CDK4 and promote cell cycle progression, but that
accumulated cyclin D1 engages in a negative feedback loop
to limit or modulate the response to androgen stimulation.
In the prostate, it is proposed that cyclin D1 acts as a rheostat to
control the strength and duration of androgen stimulation and
AR activity.
Despite the importance of cyclin D1 in eliciting and modulating
the androgen response in prostate cancer, few studies have
examined the expression profile of this protein in localised
tumours or evaluated its relevance for disease progression. We
examined 138 human radical prostatectomy samples for cyclin D1
expression, as compared to normal prostatic epithelia. We show
that whereas cyclin D1 expression is low or absent in non-
neoplastic tissue, its levels are increased in the majority of
localised tumours. Surprisingly, four distinct expression profiles
were observed in these tumour sets, wherein a large fraction of
cyclin D1-positive tumours showed cytoplasmic restriction.
Expression profiles showed some grade specificity, wherein
nuclear cyclin D1 staining emerged almost exclusively in the
higher grade tumours. Additionally, PSA expression was lower in
the cyclin D1-positive tumours, indicating that cyclin D1 status
may affect expression of serum markers that are dependent
on AR activity. The relevance of cyclin D1 status to the
proliferative index was also considered, wherein tumours with
predominantly cytoplasmic cyclin D1 exhibited the lowest
proliferative index, even as compared to cyclin D1-negative
tumours. Lastly, nuclear p21
Cip1 status was investigated, and
p21
Cip1 levels frequently associated with a more proliferative and
predominantly nuclear cyclin D1 phenotype. Together, the data
herein is the first to demonstrate that cyclin D1 can be
differentially expressed in prostate cancer, and that the status
and/or localisation of cyclin D1 expression are associated with
meaningful changes in tumour marker expression and proliferative
indices.
MATERIALS AND METHODS
Tissue procurement
Formalin-fixed paraffin-embedded serial sections (5mm) were
obtained from 36 patients that were diagnosed with prostate
cancer and underwent radical prostatectomy at the University of
Cincinnati Hospital between 2000 and 2004 in accordance with
institutional review board standards. Adjacent, non-neoplastic
tissue was associated with 23 samples and preoperative PSA values
were available for 20 patients. Additionally, three separate lymph
node samples with metastatic prostate cancer were obtained.
Human prostate tissue microarray slides containing individual
tumour cores (1.5mm diameter, 5mm) were purchased. One array
(TA1) contained 80 cores (PR801; US Biomax, Ijamsville, MD,
USA), whereas the other array (TA2) contained 49 cores with nine-
matched normal tissue and 35 associated PSA values (IMH-303;
Imgenex, San Diego, CA, USA). All patient tumours and tissue
microarrays were evaluated and graded by a pathologist according
to established guidelines (Epstein et al, 2006).
Immunohistochemistry
Immunohistochemical staining for cyclin D1 and Ki-67 was
performed using a BenchMark automated stainer (Ventana,
Tucson, AZ, USA) using the avidin–biotin peroxidase technique
following standard protocols. Staining for cyclin D1 was
performed, on all samples, according to manufacturer specifica-
tions (P2D11F11; Ventana, Tucson, AZ). Staining for Ki-67 (1:25,
MIB-1; DAKO, Carpinteria, CA, USA) was performed using a
subset of 22 samples from the 36 patient samples and one tissue
microarray (TA1). Positive and negative controls for both
antibodies gave the expected results. Immunohistochemistry for
p21
Cip1 (1:1000, SC-397; Santa Cruz, CA, USA) and AR (1:5000,
SC-816; Santa Cruz, CA, USA) was performed using a Vectastain
Elite ABC rabbit staining kit according to manufacturer specifica-
tions (Vector Laboratories, Inc., Burlingame, CA, USA). Briefly, a
subset of 16 patient samples and all three lymph node metastatic
samples were de-paraffinised in xylene and rehydrated to 70%
ethanol. Antigen retrieval was achieved in a 600W microwave
using an antigen unmasking solution (Vector Laboratories, Inc.,
Burlingame, CA, USA). Following staining, the antigen was
visualised using diaminobenzidine substrate for peroxidase using
a 2min development (DAKO, Carpinteria, CA, USA) and counter-
stained with haematoxylin.
Scoring and statistical analysis
Nuclear and cytoplasmic cyclin D1 staining intensity was assessed
before the clinical parameters (MPR) and semi-quantitatively
scored as 0 (absent), 1- (weak/focal o10% of sample), 1þ (weak
intensity o25% of sample), 2þ (moderate intensity 25–50% of
sample), or 3þ (strong intensity 450% of sample). The
percentage of nuclear Ki-67 and p21
Cip1 were counted without
knowledge of the clinical data, using a 10 10 grid eyepiece at
 20 magnification. Prostate and metastatic tumour samples were
assessed by counting nine separate fields, whereas only five
separate fields could be counted for each tumour core on the
microarray. Approximately 600 cells were counted in each field.
The data were plotted by Graph Pad Prism (v4.0) using the
mean7standard error (s.e.m.) or by scatter plot with the mean
value. Statistical analysis was also performed and correlations were
determined by linear regression. Significant differences (Po0.05)
between multiple groups were determined by one-way analysis of
variance using Kruskal–Wallis with a Dunn’s multiple comparison
post hoc test of all pairwise comparisons, or by two-tailed t-test for
two group comparisons.
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Disparate localisation of cyclin D1 is associated with
prostate tumour grade
To dissect the expression patterns of cyclin D1 in prostate cancer,
an initial cohort of 36 human primary prostate adenocarcinomas
was examined by immunohistochemistry. Of these, matched non-
neoplastic adjacent tissues were available for 23 specimens. The
Gleason and cyclin D1 scores were assessed for each patient
specimen (Figure 1A). In agreement with the literature (Han et al,
1998; Aaltomaa et al, 1999; Murphy et al, 2005), cyclin D1 was
absent in the majority of non-neoplastic prostate tissue (20/23)
and of the three positive cases one exhibited weak/focal staining.
These data are consistent with the low proliferative index of adult
prostatic epithelia. Interestingly, of the cyclin D1-positive tumours
(34/36), disparate cyclin D1 staining was observed in the tumour
regions. Staining was confined to the epithelial-derived tumour
cells, and stromal regions were negative in all cases. At least four
distinct cyclin D1 expression patterns were identified (Figure 1B).
First, the majority of tumours scored high for cytoplasmic cyclin
D1 with little or no nuclear cyclin D1 reactivity (25/36). Second, a
Cyclin D1 localisation in cancer and normal prostate
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Figure 1 Disparate localisation of cyclin D1 in localised prostate carcinoma is tumour grade specific. (A). Summary of cyclin D1 immunohistochemistry in
human primary prostate tumours (n¼36). Tumours are grouped according to Gleason and cyclin D1 scores. (B). Representative cyclin D1
immunohistochemical images ( 40 magnification) from primary prostate tumours displaying four different localisation patterns: negative, higher cytoplasmic
than nuclear (C4N), cytoplasmic equal to nuclear (C¼N), and higher nuclear than cytoplasmic (CoN). (C). Non-neoplastic (J), nuclear (K), and
cytoplasmic ( ) cyclin D1 scores for each Gleason grade were averaged from Figure 1A, and presented as mean7s.e.m. Only values with more than one
determination are shown. Statistical differences from non-neoplastic are indicated (*) and described in the Results section.
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(5/36). Third, a similar number of cases showed equivalent cyclin
D1 staining in both the nuclear and cytoplasmic compartments
(4/36). The fourth pattern was represented by those tumours
devoid of cyclin D1 (2/36). These data are consistent with the in
vitro observations that cyclin D1 can be stringently regulated as a
function of subcellular localisation (Alt et al, 2000; Radu et al,
2003) and reveal that distinct localisation patterns are observed in
prostate cancer.
Previous studies have shown that cyclin D1 activity is strongly
influenced by its subcellular localisation (Diehl and Sherr, 1997;
Barr and Johnson, 2001; Lin and Gelman, 2002; Balasenthil et al,
2004; Alao et al, 2006; Sumrejkanchanakij et al, 2006). Given the
distinct patterns of localisation observed in the initial cohort of
prostatectomy specimens, the prevalence of cyclin D1 staining
patterns was examined as a function of tumour grade. Cytoplasmic
cyclin D1 staining was significantly increased in tumours
compared to non-neoplastic tissue (po0.05) and appeared to be
predominant in Gleason 6 and 7 tumours (Figure 1C). By contrast,
nuclear cyclin D1 emerged in higher grade tumours (Gleason 8 and
9) and was also accompanied by high cytoplasmic cyclin D1
staining. Importantly, a positive linear association between
Gleason score and nuclear cyclin D1 was observed (Po0.01).
These data indicate that disparate cyclin D1 staining patterns
correlated with specific tumour grades.
To challenge further these observations, the initial cohort was
expanded to include two different human prostate carcinoma
tissue microarrays (Table 1, TA1 and TA2). For clarity, the cases
are presented separately by cohort and annotated by Gleason score
and cyclin D1 localisation pattern. As shown, the four identified
staining patterns observed in the initial cohort (Figure 1A) were
also observed in each tissue microarray. As expected, all 15 non-
neoplastic cases were cyclin D1-negative. Of the combined 102
tumour specimens, the largest fraction scored negative for cyclin
D1 (40 and 62.2%; TA1 and TA2, respectively) suggesting that
cyclin D1 expression is not requisite for tumour maintenance.
Cytoplasmic restriction of cyclin D1 staining was also observed
(9.2 and 16.2%, TA1 and TA2, respectively), and this class was
associated with the lower Gleason scores. As in the initial cohort,
tumours in the microarray with a high Gleason score maintained,
cytoplasmic cyclin D1, but tended to be accompanied by higher
nuclear cyclin D1. Combined, these data provide evidence that
cyclin D1 expression is increased and shows distinct localisation
patterns in localised disease, wherein these patterns are altered as a
function of Gleason score.
Cyclin D1 expression in metastatic prostate carcinoma
The unique patterns of cyclin D1 in localised tumours prompted
us to investigate cyclin D1 expression in metastatic tumours. For
these studies, cyclin D1 localisation was evaluated in lymph node
metastases obtained from three individual patients. Haematoxylin
and eosin (H&E) staining of all three cases revealed a similar
morphology with densely packed and disorganised tumour cells
and no glandular structure (Figure 2, left panel and data not
shown). All three metastatic tumours stained nuclear positive for
the AR, thus validating the tumour cells as prostatic in origin
(Figure 2, middle panel and data not shown) Although the
available sample size is small, all tumours exhibited exclusively
modest (1þ) nuclear cyclin D1 staining (Figure 2, right panel and
data not shown), whereas the surrounding stromal tissue was null
for cyclin D1. These results suggest that cyclin D1 localization may
be altered in lymph node metastases, wherein cyclin D1 expression
is low and confined to the nucleus.
Cyclin D1 status is inversely associated with PSA levels
Cyclin D1 has the potential to regulate both cellular proliferation
and AR-dependent transcription in prostate cancer cells (Burd
et al, 2006a). Therefore, a link between the expression of cyclin D1
and PSA, an AR target gene, was examined. For these studies, the
impact of cyclin D1 status on AR function was assessed using
preoperative PSA levels. Of all the tumours examined, preoperative
PSA levels were available for 53 patients. From the available
specimens, 23 (43.3%) were cyclin D1-negative and 30 (56.6%)
were cyclin D1-positive (Figure 3). As shown, the mean
PSA value for the cyclin D1-positive group (15.574.03ngml
 1)
was significantly lower than the cyclin D1-negative group
Table 1 Immunohistochemical summary of cyclin D1 in tissue micro-
arrays
Cyclin D1 localisation
n Cyclin D1 negative C4N
a C¼NC oN
TA1, TA2
b
Normal
c 15 6, 9 — — —
Tumour
Gleason
6 34 8, 13 (61.7)
d 1, 3 (11.8) 4, 1 (14.7) 2, 2 (11.8)
7 25 4, 4 (32.0) 3, 1 (16.0) 2, 1 (12.0) 9, 1 (40.0)
8 33 9, 4 (39.4) 2, 2 (12.1) 2, 1 (9.10) 13, 0 (39.4)
9 4 2, 1 (75.0) — — 0, 1 (25.0)
10 6 3, 1 (66.7) — — 1, 1 (33.3)
102 40, 62.2
e 9.2, 16.2 12.3, 8.1 38.5, 13.5
aC¼cytoplasmic, N¼nuclear.
bNumber of cases separated by tissue microarrays
(TA1,TA2).
cNon-neoplastic.
dPercentage of cases by Gleason score.
ePercentage of
cases by individual tissue microarray.
H&E 
20
AR 
40
Cyclin D1 
40
Figure 2 Cyclin D1 expression in metastatic prostate carcinoma. Representative immunohistochemical images from prostate-derived lymph node
metastatic tumours. Left panel: Haematoxylin and eosin staining showing disorganised architecture of the metastatic tumours. Middle panel: Strong nuclear
positive AR staining in the majority of tumour cells. Right Panel). Low nuclear cyclin D1 staining (score of 1þ). Arrows indicate tumours cells with evident
positive staining. Magnification: Left (H&E),  20; middle and right (Haematoxylin counterstained),  40.
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 1)( Po0.05). Unfortunately, there was insuffi-
cient statistical power to separate the PSA values according to
cyclin D1 localisation or Gleason score (data not shown). However,
these data are consistent with the established ability of cyclin D1 to
suppress AR function and suggest that cyclin D1 status may
influence factors relevant to prostate cancer diagnosis.
Cyclin D1 localisation impacts proliferative status in
prostate carcinoma
The ability of cyclin D1 to control transcription factor activity is
appreciated in a multitude of tissues. However, the canonical role
of cyclin D1 is in its ability to promote cellular proliferation. The
relevance of cyclin D1 localisation, in particular cytoplasmic
localisation, to proliferative status has not been evaluated. To test
this, representative tumours from each cyclin D1 staining category
were processed to quantify the proliferative indices by Ki-67
immunoreactivity. Specific staining for Ki-67 was indicated by the
absence of immunoreactivity in the adjacent matched-normal
tissue or in the stromal regions. The raw Ki-67 data with
representative images are provided in Figure 4A, and grouped
according to cyclin D1 localisation and Gleason score. A scatter
analysis between Gleason score and Ki-67 status was assessed in
the patient tumours and tissue microarray, and regression analysis
was similar for each group (data not shown). These data are
consistent with previous reports (Baretton et al, 1999) and
provided confidence in the combined dataset. As expected, a
significant positive correlation between localised tumour score and
proliferation was determined (Po0.05), and the highest average
proliferative index came from the metastatic tumours (Figure 4B).
When the impact of cyclin D1 localisation on proliferation was
examined (Figure 4C), a statistically significant (Po0.01) differ-
ence was identified between predominately cytoplasmic cyclin D1
(4.3370.63) and predominately nuclear cyclin D1 (12.572.77)
tumours. The proliferative status of the cytoplasmic cyclin D1
tumours were typically lower than the cyclin D1-negative
(7.2571.34) tumours, although this did not reach statistical
significance. This potentially interesting observation may suggest
that cytoplasmic localisation may play a role in suppressing
cellular proliferation. Furthermore, these data support the role of
nuclear cyclin D1 as an initiator of cell cycle progression, where it
is able to bind and activate CDK. However, it should be noted that
a number of cyclin D1-positive tumours in all three localisation
groups had a low proliferative index (Figure 4C), demonstrating
that cyclin D1 expression itself is not sufficient to induce cellular
proliferation.
Contribution of p21
Cip1 to proliferation and progression of
prostate carcinoma
Although the mechanisms governing cyclin D1 localisation are not
completely understood, p21
Cip1 is a key modulator of both cyclin
D1 activity and its subcellular localisation. Interaction of p21
Cip1
with cyclin D1/CDK is known to promote stabilisation and nuclear
import of the complex, resulting in enhanced CDK activity (Parry
et al, 1999; Gladden and Diehl, 2005). Similarly, p21
Cip1 has been
shown to be increased in prostate cancer and holds potential merit
as a prognostic indicator (Matsushima et al, 1998; Sarkar et al,
1999; Omar et al, 2001; Rigaud et al, 2004). To determine the
relevance of p21
Cip1 to cyclin D1 localisation and proliferation,
p21
Cip1 immunoreactivity was assessed in a subset of patient
tumours (n¼16) and the three metastatic tumours wherein cyclin
D1 and Ki-67 status had been determined. All three metastatic
tumours and 11 of the 16 primary tumours (68.8%) were p21
Cip1-
positive. The range of p21
Cip1 staining was between 1.41–12.9% of
the tumour specimens. A positive trend was observed between
tumour grade and nuclear p21
Cip1, but these data did not reach
statistical significance (Figure 5A). However, a significant positive
correlation was identified between nuclear p21
Cip1 and Ki-67 with
an r
2 of 0.72 (Figure 5B). Separation by cyclin D1 localisation
indicated that samples with higher nuclear cyclin D1 are likely to
have higher nuclear p21
Cip1 (Figure 5C), as the mean percent
nuclear p21
Cip1 for the cyclin D1 groups were: C4N (2.0470.57),
C¼N (2.5371.71), and CoN (8.9973.91). However, no obvious
trends were identified between p21
Cip1 and PSA or Gleason score
(data not shown). Together, these data suggest that p21
Cip1 levels
likely contribute more towards nuclear than cytoplasmic localisa-
tion of cyclin D1, and that increased nuclear p21
Cip1 levels may be
associated with a more proliferative or advanced disease.
DISCUSSION
It has been previously shown through in vitro studies that cyclin
D1 can influence androgen-dependent prostate cancer cell
proliferation through its dual ability to modulate both CDK4 and
AR activity (Petre-Draviam et al, 2005; Burd et al, 2006a). To
elucidate further the role of cyclin D1 in prostate cancer, primary
human prostate cancer specimens were utilised to assess the
influence of cyclin D1 expression and localisation on PSA levels
and proliferation index. The present findings demonstrate that
cyclin D1 expression is enhanced in the majority of localised
tumours as compared to non-neoplastic epithelia, thus indicating
that cyclin D1 is aberrantly regulated in prostate cancer.
Remarkably, cyclin D1-positive tumours displayed distinct locali-
sation patterns, wherein tumours frequently exhibited predomi-
nately cytoplasmic cyclin D1. Investigations to challenge the
impact of cyclin D1 expression revealed that cyclin D1-positive
tumours associated with significantly lower preoperative PSA
values, indicating that cyclin D1 status may influence tumour
marker expression. Furthermore, there was a trend for tumours
with predominately cytoplasmic cyclin D1 to harbour low
proliferative potential as compared to tumours with predominately
nuclear cyclin D1. Finally, expression of nuclear p21
Cip1,a n
important mediator of cyclin D1 action, correlated with prolifera-
tion and was associated with predominately nuclear cyclin D1, thus
providing a potential mechanism for the differential localisation
patterns of cyclin D1. Combined, these data suggest that cyclin D1
expression and localisation may influence proliferation and
diagnostic factors in prostate cancer.
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Figure 3 Cyclin D1 status inversely associates with PSA levels.
Combined preoperation PSA values (ngml
 1) separated as negative
(n¼24) and positive (n¼29) for cyclin D1 and presented as a scatter plot.
Average preoperative PSA values for the cyclin D1-positive and -negative
tumours were statistically different (Po0.05). Average values for each
group are described in the Results section.
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in primary prostatic adenocarcinomas, and the criteria used to
establish positive cyclin D1 staining have been divergent. The
majority of studies have focused largely on nuclear cyclin D1, but
common conclusions have failed to emerge. For example, using a
staining cutoff of 410%, a trend for increased nuclear cyclin D1
with high Gleason scores (X7) was observed but not considered
significant (Kallakury et al, 1997). A separate study, using a low
(o20%) -vs- high (420%) nuclear cyclin D1 staining criteria,
reported only 12% of primary tumours with high cyclin D1
(Drobnjak et al, 2000). In the present analyses, quantification of all
cyclin D1 localisation patterns was considered. Using this inclusive
approach, 63% of tumours and only 8% of normal epithelia scored
positive for cyclin D1 (Table 1), indicating that the protein is
accumulated in prostate cancer. These data are congruent with a
large study of 187 tumours, wherein 71% were scored cyclin D1-
positive, with some cytoplasmic cyclin D1 noted but not quantified
(Aaltomaa et al, 1999). Here, nuclear cyclin D1 correlated with
Gleason score and proliferation, as is also consistent with our
results (Figures 1C and 4C, respectively). A series of smaller
studies have also reported cyclin D1 induction in tumours
compared to normal specimens (Han et al, 1998; Kolar et al,
2000; Murphy et al, 2005) and at least one of these considered all
cyclin D1 localisations (including cytoplasmic and perinuclear) as
positive, although correlates according to localisation were not
considered (Han et al, 1998). Thus, the data herein confirm that
increased cyclin D1 is seen with high frequency in prostate cancer,
and is the first to provide a detailed assessment of cyclin D1
localisation patterns and correlates in organ-confined disease.
The impact of cyclin D1 localisation patterns in metastatic
disease is less certain. This study examined only three prostate-
derived metastatic tumours, all of which showed low nuclear cyclin
Ki-67 in prostate tumours and metastasis
Group Gleason Ki-67% ↑Tumour
Negative
C>N
C=N
C<N
C>N C=N
Cyclin D1 localisation
C<N
TA1 6 1.41
11.6
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10.4
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3.21
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4.04
3.12
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13.3
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Figure 4 Cyclin D1 status impacts proliferation in prostate carcinoma. (A) Summary of nuclear Ki-67 (%) immunohistochemistry for a subset
of patient tumours (n¼22), a tissue microarray (TA1, n¼36), and the metastatic tumours (n¼3). Tumours are grouped according to cyclin D1 localisation
as described in Figure 1B and ranked by Gleason grade. (B) Histograph of Ki-67 (%) as a function of tumour progression (n¼22); the data (Mean7s.e.m.)
were derived from Figure 1A. A positive correlation between tumour progression and Ki-67 (%) was seen (Po0.05). (C) Ki-67 (%) were separated
according to cyclin D1 localisation and presented as a scatter plot. Note: A number of D1-positive tumours in all the three localisation groups demonstrated
low proliferation. The average Ki-67 (%) for C4N was statistically different than CoN( Po0.01). Average values for each group are described in the Results
section.
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sD1 staining and lacked cytoplasmic staining (Figure 2). Consistent
with these results, previously reported data have shown that
84% of lymph node metastases lack significant cyclin D1 staining
(Kallakury et al, 1997). In contrast, a second study assessed
nuclear cyclin D1 in bone metastatic tumours and determined that
a large fraction (68%) of these specimens contained cyclin D1
(Drobnjak et al, 2000). These data suggest that cyclin D1 may hold
a more pronounced role for proliferation in bone metastases
compared to lymph node deposits. Consistent with a role for cyclin
D1 in the proliferation of bone metastatic tumours from prostate,
others have reported correlations between metastatic cyclin D1
expression derived from other tumour types (Chhieng et al, 1998).
Given these observations, the concept that cyclin D1 prevalence
and localisation may vary depending on metastatic site is
intriguing and should be more rigorously considered.
Regardless of the site, the mechanism(s) by which cyclin D1
accumulates in prostate cancer cells remains to be discerned.
Cyclin D1 levels are typically under stringent regulation, but
aberrant cyclin D1 expression has been implicated as having
oncogenic properties in many neoplasias including breast (Arnold
and Papanikolaou, 2005), pituitary (Faglia and Spada, 2001), and
squamous cell carcinoma (Nadal and Cardesa, 2003). Overexpres-
sion of cyclin D1 may occur through multiple mechanisms,
including chromosomal translocation events (e.g. Mantle cell
lymphomas (Bigoni et al, 1996)), gene amplification (common in
breast (Buckley et al, 1993) and oesophageal cancers (Jiang et al,
1993)), and defects in protein processing or transport (Gladden
and Diehl, 2005). The propensity of selected tumour types to
induce cyclin D1 accumulation in cancer may therefore be a
heterogenous and complex event that culminates in a similar
phenotype. Although genetic abnormalities in prostate cancer have
been reported for other important cell cycle regulators such as
phosphatase and tensin homologue (Majumder and Sellers, 2005),
the retinoblastoma tumour suppressor protein (RB), and p53
(MacGrogan and Bookstein, 1997), perturbations in cyclin D1
appear to be less common. For example, cyclin D1 gene
amplification did not increase in benign prostatic hyperplasia
(BPH) or primary and refractory tumours of the prostate (Linja
et al, 2004). Similarly, others have shown low cyclin D1 gene
amplification (4%) in primary prostate tumours (Gumbiner et al,
1999) and, depending on the method of detection, 5–15% gene
amplification in advanced prostate tumours (Bubendorf et al,
1999; El Gedaily et al, 2001). Thus, it is unlikely that the induction
of cyclin D1 observed herein is a result of gene amplification.
Recent studies in prostate cancer model systems have shown that
cyclin D1 accumulates after androgen stimulation as a result of
mTOR activation and resultant enhancement of cyclin D1 mRNA
translation (Xu et al, 2006). However, the mechanisms underlying
androgen-mediated mTOR induction remain elusive. Future
studies directed at delineating mTOR activation may assist in
revealing the mechanism(s) by which cyclin D1 accumulates in
prostate cancer.
Once cyclin D1 protein accumulates, it is often regulated by
subcellular localisation and proteasome-dependent degradation
(Diehl et al, 1998; Germain et al, 2000). Our data indicate that
this process, in part, is likely to be responsible for the disparate
localisation of cyclin D1 in prostate cancer. The present finding
that prostate cancer cells frequently exhibit cytoplasmic cyclin D1
is novel, but not without precedent. For example, elevated cyclin
D1 with cytoplasmic cyclin D1 staining has been reported in many
different tumour types, such as colorectal (Handa et al, 1999; Khor
et al, 2006), pancreatic (Culhaci et al, 2005), lung (Dworakowska
et al, 2005), thyroid (Temmim et al, 2006), and bladder (Sudo et al,
2003). Despite these observations only a handful of studies have
addressed the functional consequence of cytoplasmic cyclin D1. It
has been suggested that cytoplasmic cyclin D1 is more common
in colorectal tumours deficient for b-catenin (Kuramochi et al,
2006); however, b–catenin has been shown to regulate cyclin D1
expression in colon cancer cells (Tetsu and McCormick, 1999). In
pituitary (Hibberts et al, 1999; Simpson et al, 2001) and ovarian
(Dhar et al, 1999) tumours, cytoplasmic cyclin D1 has been
reported (35 and 59% of cyclin D1-positive cases, respectively) but
no correlations were identified. In hepatocellular carcinomas,
cytoplasmic cyclin D1 appeared to significantly correlate with
prognostic factors like intrahepatic metastasis (Sato et al, 1999). A
large study which assessed cyclin D1 localisation was performed
with 150 transitional cell carcinomas of the bladder, wherein
cytoplasmic cyclin D1 increased with disease progression and
correlated with decreased survival (Tut et al, 2001). This contrasts
with our findings, wherein predominately cytoplasmic cyclin D1
correlated with lower Gleason scores (Figure 1C and Table 1) and
exhibited the lowest proliferation index (Figure 4C). Furthermore,
the proliferative index tended to be lower in the cytoplasmic cyclin
D1 tumours than in the cyclin D1-deficient tumours. This
observation suggests that restriction of cyclin D1 to the cytoplasm
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Figure 5 Contribution of p21
Cip1 expression in prostate carcinoma.
Scatter plots characterising nuclear p21
Cip1 (%) in a subset of patient
tumours (PT1, n¼16), which had been immunostained for cyclin D1 and
Ki-67. (A) A trend between increased nuclear p21
Cip1 and Gleason score
was observed. (B) A positive correlation by linear regression was identified
between increased nuclear p21
Cip1 and Ki-67 (%) (r
2¼0.72). (C) Tumours
with more nuclear D1 appear to have more nuclear p21
Cip1. Average
values for panels A and C are described in the Results section.
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smay allow suppression of cellular proliferation but requires a more
rigorous investigation. Interestingly, a number of colorectal cancer
studies have observed cytoplasmic cyclin D1 in tumour specimens
(Palmqvist et al, 1998; Handa et al, 1999; McKay et al, 2000;
Holland et al, 2001; Khor et al, 2006; Kuramochi et al, 2006) and at
least one of these studies has reported that increased cytoplasmic
cyclin D1 correlated with low proliferation (Palmqvist et al, 1998).
This result is similar to our analyses (Figure 4C), wherein tumours
with predominately cytoplasmic cyclin D1 showed a significantly
lower proliferative index. In the case of prostate cancer, one
mechanism could be through the ability to directly repress AR
activity or sequester it from its nuclear targets. Alternatively,
prostate cancer cells may have invoked mechanisms to bypass the
cyclin D1 requirement (e.g. RB loss), thereby weakening the
necessity to induce cyclin D1 accumulation (Lukas et al, 1995).
However, it should be emphasised that our data also suggests that
cyclin D1-positive status does not predict a high proliferative index
(Figure 4C). Combined, these data support the contention that
cyclin D1 is differentially localised in cancer, and that cytoplasmic
cyclin D1 can correlate with proliferative outcomes in a tissue
specific manner.
The emergence of nuclear cyclin D1 in the high Gleason scores is
intriguing, and this localisation pattern correlated with a higher
proliferative index. These observations are consistent with the
ability of nuclear cyclin D1 to enhance CDK4 activity and promote
G1-S progression. The delineation of the mechanism(s) by which
nuclear emergence is facilitated will likely reveal new insights
into advanced prostatic disease. One exciting possibility to be
considered concerning nuclear cyclin D1 is the contribution of
cyclin D1b, a splice variant of cyclin D1 that is restricted from
nuclear export (Lu et al, 2003). Attempts to develop a suitable
cyclin D1b-specific antibody for immunohistochemistry have had
limited success (data not shown). However, we have recently
shown that cyclin D1b is upregulated in human prostate tumours,
is selectively compromised for AR regulation, and may yield a
specific growth advantage (Burd et al, 2006b). Therefore, future
investigations will be directed at assessing cyclin D1b in tumours
as a function of disease progression.
In addition to the effects on proliferation, previous data in
prostate cancer cell lines suggest that cyclin D1 has specialised
roles concerning AR function in the control of prostate cancer
cellular function. Supporting this view, the present analyses
revealed that cyclin D1 status can significantly correlate with
serum PSA levels (Figure 3). Specifically, cyclin D1-positive
tumours were more likely to be derived from patients with lower
preoperative PSA values, perhaps reflective of the established
ability of cyclin D1 to modulate AR function. This contention is
consistent with previous reports, which observed a correlation
between low cyclin D1 and elevated preoperation PSA values
(410ngml
 1) (Drobnjak et al, 2000). On the basis of the PSA and
proliferation data obtained in our study, it is conceivable that a
subset of cyclin D1-positive tumours may exist that have increased
proliferation and have low PSA values. The mechanism(s) and
consequences of this observation will be of significant clinical
interest, as these data indicate that cyclin D1 status may suppress
tumour marker expression. Moreover, these data highlight the
need to consider the effects, mediated by regulatory elements of
proliferation (i.e. cyclin D1), on tumour marker expression.
As these collective findings indicated that cyclin D1 status and
localisation patterns may impinge upon critical parameters,
potential mechanism(s) underlying the differential cyclin D1
patterns were investigated. Here we show that p21
Cip1, which has
been shown to positively regulate cyclin D1 accumulation, nuclear
translocation, and CDK4 activation, is likely to contribute to the
differential patterns observed. Specifically, we showed a trend for
increased p21
Cip1 levels with tumour progression and that p21
Cip1
is potentially elevated in tumours with high nuclear cyclin D1
(Figure 5A and C). These observations are consistent with
observations in other tumour types (McKay et al, 2000; Holland
et al, 2001; Tut et al, 2001) and support its role in promoting cyclin
D1/CDK4 activity. Second, we showed that p21
Cip1 levels correlate
with proliferation (Figure 5B), thus confirming other reports
(Ljung et al, 1997; Baretton et al, 1999; Osman et al, 1999; Fizazi
et al, 2002). Collectively, these data indicate that p21
Cip1 action in
this tumour type likely favours proliferation. Similar conclusions
about the role of p21
Cip1 have been seen in other tumour types
such as breast cancer (Elledge and Allred, 1998). These studies
indicate that p21
Cip1 is a likely effector of cyclin D1 accumulation,
localisation, and activity in multiple tumour types, including
prostate.
In summary, the data herein demonstrate that whereas cyclin D1
is generally elevated in localised prostate cancer, differential
localization of cyclin D1 may influence clinicopathological
parameters. The present data support a model wherein cyclin D1
accumulation and localisation are regulated as a function of
tumour grade, and that differential cyclin D1 status significantly
correlates with proliferation and PSA values. Further analyses
revealed that p21
Cip1 may play a role in regulating cyclin D1
dynamics and likely contributes to the observed alterations in
tumour characteristics. Together, these studies associated differ-
ential expression and localisation of cyclin D1 with important
clinicopathological parameters and suggest new insight concerning
the potential consequence of cyclin D1 induction in prostate
cancer.
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